Endocare Secures Financing for Further Middle East Expansion

Endocare, a pioneering metabolic health company focused on integrating innovation with personalised treatment, has successfully closed a major funding round to support its expansion into the Middle East. This achievement represents a key milestone in the company’s journey to scale its operations and further its mission of delivering state-of-the-art healthcare solutions across the region.

RbetaQ Holding Leads Strategic Investment Initiative

The financing round was led by RbetaQ Holding, a Germany-based family office known for backing forward-thinking healthcare and tech ventures. With this investment, Endocare will accelerate its market entry into the UAE and Saudi Arabia, bringing its advanced health solutions to two of the region’s most dynamic healthcare markets.

Tackling the Region’s Rising Metabolic Health Needs

Endocare’s foundation is built on a blend of scientific excellence and patient-centred care, positioning it strongly to respond to the increasing demand for metabolic and obesity-related treatments. In cities like Dubai, where public health concerns around weight management are growing, Endocare aims to deliver personalised, effective, and lasting solutions for an increasingly health-aware population.

Prof. Dr Ashok Kaul Joins Board to Strengthen Innovation

In a move that further bolsters its leadership, Endocare has appointed Prof. Dr Ashok Kaul to its board of directors. A renowned authority in data science, artificial intelligence, and technology, Dr Kaul’s expertise will play a vital role in guiding the company’s strategic direction, particularly in translating innovation into real-world clinical impact.

“The closing of our financing round and Dr Ashok Kaul’s addition to our board mark pivotal moments in Endocare’s evolution,” said Leyla Azizova, Co-Founder and CEO of Endocare. “We are excited to accelerate our regional expansion while continuing to innovate and deliver exceptional care for our patients — not only in the areas of metabolic health and weight management, but also in promoting longevity through science-backed lifestyle interventions.”

Commenting on his new role, Dr. Ashok Kaul said: “Endocare’s vision of transforming metabolic healthcare through innovation aligns perfectly with my passion for leveraging technology to improve lives. I look forward to working with the team to drive impactful change in the region’s healthcare landscape.”

Commitment to Technology-Driven Patient Care

As part of its growth strategy, Endocare is heavily investing in technology-enabled healthcare solutions designed to improve patient outcomes and streamline treatment pathways. These efforts highlight the company’s focus on fusing medical science with digital innovation to elevate the standard of metabolic care in the region.

A Regional Vision Rooted in Evidence-Based Care

With a strong base in Dubai, Endocare is now preparing to extend its footprint across the Middle East. By staying true to its evidence-based, patient-first philosophy, the company aims to tackle regional healthcare challenges and empower individuals to live longer, healthier lives.